TRxADE HEALTH Competitors

Ayala Pharmaceuticals (NASDAQ:AYLA) and TRxADE HEALTH (NASDAQ:MEDS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Ayala Pharmaceuticals and TRxADE HEALTH's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Ayala Pharmaceuticals and TRxADE HEALTH's revenue, earnings per share (EPS) and valuation.

TRxADE HEALTH has higher revenue and earnings than Ayala Pharmaceuticals.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ayala Pharmaceuticals and TRxADE HEALTH, as provided by MarketBeat.com.

Ayala Pharmaceuticals currently has a consensus price target of $24.00, indicating a potential upside of 120.69%. TRxADE HEALTH has a consensus price target of $12.50, indicating a potential upside of 177.78%. Given TRxADE HEALTH's higher possible upside, analysts clearly believe TRxADE HEALTH is more favorable than Ayala Pharmaceuticals.

Insider & Institutional Ownership

15.5% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 13.7% of TRxADE HEALTH shares are held by institutional investors. 2.9% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 53.3% of TRxADE HEALTH shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

TRxADE HEALTH beats Ayala Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Synaptogenix (NASDAQ:SNPX) and TRxADE HEALTH (NASDAQ:MEDS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Analyst Ratings

This is a summary of recent recommendations for Synaptogenix and TRxADE HEALTH, as provided by MarketBeat.com.

TRxADE HEALTH has a consensus price target of $12.50, indicating a potential upside of 177.78%. Given TRxADE HEALTH's higher probable upside, analysts plainly believe TRxADE HEALTH is more favorable than Synaptogenix.

Institutional and Insider Ownership

13.7% of TRxADE HEALTH shares are held by institutional investors. 53.3% of TRxADE HEALTH shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Synaptogenix and TRxADE HEALTH's top-line revenue, earnings per share and valuation.

Synaptogenix has higher earnings, but lower revenue than TRxADE HEALTH.

Profitability

This table compares Synaptogenix and TRxADE HEALTH's net margins, return on equity and return on assets.

Summary

TRxADE HEALTH beats Synaptogenix on 5 of the 8 factors compared between the two stocks.

TRxADE HEALTH (NASDAQ:MEDS) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Valuation and Earnings

This table compares TRxADE HEALTH and scPharmaceuticals' revenue, earnings per share (EPS) and valuation.

TRxADE HEALTH has higher revenue and earnings than scPharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TRxADE HEALTH and scPharmaceuticals, as provided by MarketBeat.com.

TRxADE HEALTH currently has a consensus price target of $12.50, suggesting a potential upside of 177.78%. scPharmaceuticals has a consensus price target of $11.00, suggesting a potential upside of 110.33%. Given TRxADE HEALTH's stronger consensus rating and higher possible upside, research analysts plainly believe TRxADE HEALTH is more favorable than scPharmaceuticals.

Risk and Volatility

TRxADE HEALTH has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Profitability

This table compares TRxADE HEALTH and scPharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

13.7% of TRxADE HEALTH shares are held by institutional investors. Comparatively, 62.9% of scPharmaceuticals shares are held by institutional investors. 53.3% of TRxADE HEALTH shares are held by company insiders. Comparatively, 4.1% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

TRxADE HEALTH beats scPharmaceuticals on 7 of the 11 factors compared between the two stocks.

Flora Growth (NASDAQ:FLGC) and TRxADE HEALTH (NASDAQ:MEDS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Flora Growth and TRxADE HEALTH's gross revenue, earnings per share and valuation.

Flora Growth has higher earnings, but lower revenue than TRxADE HEALTH.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Flora Growth and TRxADE HEALTH, as reported by MarketBeat.

TRxADE HEALTH has a consensus target price of $12.50, suggesting a potential upside of 177.78%. Given TRxADE HEALTH's higher possible upside, analysts clearly believe TRxADE HEALTH is more favorable than Flora Growth.

Profitability

This table compares Flora Growth and TRxADE HEALTH's net margins, return on equity and return on assets.

Institutional and Insider Ownership

13.7% of TRxADE HEALTH shares are owned by institutional investors. 53.3% of TRxADE HEALTH shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

TRxADE HEALTH beats Flora Growth on 5 of the 8 factors compared between the two stocks.

TRxADE HEALTH (NASDAQ:MEDS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

13.7% of TRxADE HEALTH shares are held by institutional investors. Comparatively, 0.5% of Longeveron shares are held by institutional investors. 53.3% of TRxADE HEALTH shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares TRxADE HEALTH and Longeveron's top-line revenue, earnings per share (EPS) and valuation.

TRxADE HEALTH has higher revenue and earnings than Longeveron.

Profitability

This table compares TRxADE HEALTH and Longeveron's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for TRxADE HEALTH and Longeveron, as provided by MarketBeat.com.

TRxADE HEALTH currently has a consensus price target of $12.50, indicating a potential upside of 177.78%. Given TRxADE HEALTH's higher probable upside, equities research analysts plainly believe TRxADE HEALTH is more favorable than Longeveron.

Summary

TRxADE HEALTH beats Longeveron on 6 of the 10 factors compared between the two stocks.

TRxADE HEALTH (NASDAQ:MEDS) and Aytu Biopharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares TRxADE HEALTH and Aytu Biopharma's net margins, return on equity and return on assets.

Volatility and Risk

TRxADE HEALTH has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Aytu Biopharma has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for TRxADE HEALTH and Aytu Biopharma, as reported by MarketBeat.

TRxADE HEALTH currently has a consensus target price of $12.50, indicating a potential upside of 177.78%. Aytu Biopharma has a consensus target price of $9.50, indicating a potential upside of 69.95%. Given TRxADE HEALTH's higher probable upside, equities research analysts plainly believe TRxADE HEALTH is more favorable than Aytu Biopharma.

Institutional & Insider Ownership

13.7% of TRxADE HEALTH shares are owned by institutional investors. Comparatively, 35.5% of Aytu Biopharma shares are owned by institutional investors. 53.3% of TRxADE HEALTH shares are owned by company insiders. Comparatively, 6.6% of Aytu Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares TRxADE HEALTH and Aytu Biopharma's revenue, earnings per share (EPS) and valuation.

TRxADE HEALTH has higher earnings, but lower revenue than Aytu Biopharma.